Use of CK-548 and CK-869 as Arp2/3 complex inhibitors directly suppresses microtubule assembly both in vitro and in vivo
- Biochem Biophys Res Commun. 2018 Feb 12;496(3):834-839. doi: 10.1016/j.bbrc.2018.01.143.
- 1. Department of Nanobiology, Graduate School of Advanced Integration Science, Chiba University, Chiba 263-8522, Japan. Electronic address: [email protected].
- 2. Department of Biology, Graduate School of Science, Chiba University, Chiba 263-8522, Japan.
- 3. Department of Nanobiology, Graduate School of Advanced Integration Science, Chiba University, Chiba 263-8522, Japan; Department of Biology, Graduate School of Science, Chiba University, Chiba 263-8522, Japan.
- 4. Department of Nanobiology, Graduate School of Advanced Integration Science, Chiba University, Chiba 263-8522, Japan; Department of Biology, Graduate School of Science, Chiba University, Chiba 263-8522, Japan. Electronic address: [email protected].
Two types of Arp2/3 complex inhibitors, CK-666/636 and CK-548/869, are commonly used to study Arp2/3 complex-dependent actin assembly both in vitro and in vivo. However, we found that CK-548 and CK-869 directly suppress microtubule (MT) assembly independent of the actin Cytoskeleton. Treatment of cultured mammalian cells with 50 μM CK-869 dramatically decreased MT networks and, instead, accumulated tubulin at the cell periphery, as did nocodazole that inhibits MT assembly. An in vitro MT-sedimentation assay revealed that CK-548 and CK-869 significantly suppressed MT polymerization. In budding yeast, although CK-548 and CK-869 are reported to lack binding abilities in the yeast Arp3, CK-548 treatment decreased cytoplasmic MT at several tens of micromolar concentrations. In addition, we found that the effects of CK-548 and CK-869 on MT assembly varied according to species. We propose that CK-548 and CK-869 are not suitable for studying the Cytoskeleton in living cells.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Arp2/3 ComplexResearch Areas: Cancer